Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality

BACKGROUND: With the use of targeted drugs in lung cancer patients, targeted drug-induced interstitial lung disease (ILD) has attracted more and more attention. The incidence, time, and severity of different targeted drug-induced ILD vary. Almonertinib/HS-10296 is a third-generation epidermal growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qian, Hu, Zhong, Li, Xin, Tang, Xiaokui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996844/
https://www.ncbi.nlm.nih.gov/pubmed/36890493
http://dx.doi.org/10.1186/s12890-023-02367-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996844/
https://www.ncbi.nlm.nih.gov/pubmed/36890493
http://dx.doi.org/10.1186/s12890-023-02367-x

Ejemplares similares